Europe gives green light to AbbVie hepatitis C medicine, others
November 21, 2014 at 07:20 AM EST
LONDON, Nov 21 (Reuters) - European regulators recommended approval for AbbVie's hepatitis C drug dasabuvir, an experimental all-oral regimen for patients infected with the virus that could be an alternative to long courses of a combination of pills and injections.